United States Pharmaceutical Contract Manufacturing Market Outlook to 2030: Size, Share, Growth and Trends

The United States Pharmaceutical Contract Manufacturing Market was valued at USD 46,200 Mn in 2024 on an industry service revenue basis. This scope captures revenue earned by U.S.-based CMO and CDMO facilities serving both domestic and international clients, while excluding in-house manufacturing by integrated pharmaceutical companies. The market is already large enough to support multiple specialized profit pools, from small-molecule API work to sterile fill-finish and advanced therapies. Structurally, its scale reflects the combination of U.S. sponsor density, regulatory depth, and sustained outsourcing of technically complex manufacturing steps.

The market is projected to reach approximately USD 70,600 Mn by 2030 , implying a 7.3% CAGR over the forecast period. Growth is expected to outpace the 2019-2024 historical CAGR of 6.1% as biologics, sterile manufacturing, and advanced therapy outsourcing gain share. The forecast also assumes continued domestic capacity investment and a higher mix of complex programs with better revenue intensity per batch. Importantly, this is not purely a volume story; the revenue premium increasingly comes from hard-to-replace technical capabilities and validated regulatory execution.

Profit pools are shifting toward complex modalities, especially advanced therapies, biologics drug substance, HPAPI-ADC work, and integrated sterile services. In 2024, Advanced Therapies represented USD 3,200 Mn and is the fastest-growing segment at 13.5% CAGR , while Biologics Drug Substance and HPAPI-ADC services add further margin-rich exposure. By contrast, Finished Dosage Form - Oral Solids & Liquids remains a large but slower-growth pool. The implication is clear: the market is moving from scale-based outsourcing toward capability-based outsourcing, where regulatory difficulty and switching costs support stronger pricing and better customer stickiness.

The largest risks are compliance failure, capacity misallocation, and exposure to lower-growth dosage-form segments. FDA conducted 972 drug quality inspections in FY2024 and issued 105 warning letters , showing that execution risk remains commercially material. A single quality event can disrupt several sponsors at once because many facilities operate multi-client networks. In parallel, mature formulation programs face ongoing pricing pressure, especially where differentiation is limited and generic activity is high. Returns therefore depend not just on filling reactors or lines, but on maintaining inspection-ready systems, modality fit, and customer mix discipline.

The East is the most commercially important region in the current market structure because it combines sponsor access, biologics talent, validation resources, and dense commercial logistics. That matters especially for tech transfer, regulatory interaction, and customer-facing project management. The South also remains strategically relevant due to expanding biologics and sterile investments, while the North and West play supporting roles in specialized manufacturing and innovation services. Region choice affects labor access, client proximity, and speed of scale-up more than headline revenue alone, so geographic strategy should be tied to the target modality and service model.

The United States is the clear scale leader among relevant peer markets. At USD 46,200 Mn in 2024 , it is materially larger than Switzerland, Germany, South Korea, Ireland, and Canada, and it combines that size with a still-strong 7.3% growth outlook . The differentiators are not only end-market demand, but also the country’s unmatched pharmaceutical R&D base and its broad manufacturing footprint regulated for the U.S. market. South Korea may grow faster in percentage terms, but the United States offers a deeper pool of customers, modalities, and acquisition targets.

The core demand driver is the scale of the U.S. pharmaceutical innovation ecosystem combined with sponsor preference for externalized manufacturing risk. NIH budget authority reached USD 48.9 Bn in 2024 , FDA approved 50 novel drugs in 2024 , and the outsourced manufacturing sector now supports a substantial share of both development and commercial supply. Sponsors increasingly use CDMOs to avoid fixed plant ownership, access specialized quality systems, and accelerate launch preparation. As programs become more complex, this demand base shifts toward fewer, more capable partners with validated technical depth.